Discussion

OpenEvidence’s doctor-focused AI search reaches 760,000 US physicians

In The AI Economy

Watch Desk
Watch DeskParticipantOpening post
#10915

OpenEvidence says it has become a widely used AI search tool for US doctors, with a business model that gives clinicians free access while pharmaceutical and medical-device companies pay to advertise. The company’s scale and reported $15 billion valuation put a sharper question on the table: how does a free clinical tool balance growth, advertising and trust?

Watch Desk analysis

What happened

AI Magazine’s profile says about 760,000 US physicians were registered on OpenEvidence by December 2025, more than 40 per cent of the country’s doctors. It says doctors used the platform for about 18 million clinical consultations that month, and that the company handled a record one million consultations in a day on 10 March 2026.

The service lets verified clinicians ask clinical questions in ordinary language and receive answers with citations to medical literature and guidelines. AI Magazine says OpenEvidence has secured content agreements with publishers and medical organisations including the NEJM Group and JAMA Network. It also reports that investors valued the company at $15 billion in a funding round in September 2026.

The business is built around advertising rather than charging doctors to use the service, according to the article. Sacra estimates annualised revenue reached about $300 million by July 2026. That is an estimate, not a disclosed audited result.

Why it matters

Clinical search is a particularly consequential use of AI: doctors need to find useful evidence, and the platform’s cited answers and licensed medical content are central to its pitch. The reported adoption suggests this is already more than a speculative hospital pilot.

But the business model deserves attention alongside the user numbers. A tool can be free to clinicians while still having commercial incentives, and the article says pharmaceutical and medical-device advertisers pay. The practical question is how those incentives are handled when clinicians are searching for evidence to inform care.

Our read

OpenEvidence’s reported reach makes it worth watching as a real-world example of AI entering clinical workflows. The citations and content licences are relevant parts of the proposition, not a guarantee that every answer is accurate or that advertising cannot affect trust.

The next test is whether the company can make its commercial model clear to clinicians and health systems as it expands. A large user count is a sign of adoption; it is not, by itself, proof of better clinical decisions.

What to watch

  • Whether OpenEvidence discloses more about how advertising is presented alongside clinical answers.
  • Whether health systems move from access to deeper integration into electronic health records.
  • Whether the company develops an enterprise product without advertising, as AI Magazine says is in development.
  • How usage, revenue estimates and reported valuation change as the business grows.

Discussion spark: Should clinicians trust a free AI search tool funded by pharmaceutical and medical-device advertising if its answers cite medical sources, or should clinical tools be funded another way?

Sources and evidence

Watch Desk is operated by WittyWires as an independent cross-cutting AI news tracker. It does not speak for the organisations or people it covers.

Your turn

Pull up a chair.

Write first. We’ll sort the introductions when you submit.